Market Overview:
The Surgical Site Infection Market size is expected to grow from USD 4.59 Billion in 2022 to USD 6.38 Billion by 2030, at a CAGR of 4.2% during the forecast period.
Surgical site infection is an infection that develops in the area of the body where surgery was performed. Sometimes infections at surgical sites are only skin deep. Infections at other surgical sites can be much more dangerous due to they can spread to deeper layers of tissue, organs, or implanted materials. The Centers for Disease Control and Prevention (CDC) publishes guidelines and tools for the medical community to help eliminate surgical site infections, and it also provides resources for the general public to learn more about these infections and take preventative measures.
Top Key Players in Surgical Site Infection Market:
3M Company, STERIS plc, Stryker Corporation, Medtronic plc, Prescient Surgical Inc., Covalon Technologies Ltd., Surgical Site Infection Prevention LLC, HARTMANN GROUP, Mölnlycke Health Care AB, Becton, Dickinson, and Company, and Other major players.
Market Dynamics and Factors for Surgical Site Infection Market:
Drivers:
Rising Incidence of Surgical Site Infection
The increasing incidence of Surgical Site Infections (SSIs) has become a significant driver for the growth of the Surgical Site Infection Market. Surgical Site Infections are one of the most common types of healthcare-associated infections, affecting patients who undergo surgical procedures. These infections pose a substantial risk to patient health, leading to prolonged hospital stays, increased healthcare costs, and sometimes even severe complications.
As the global population ages, there is a higher demand for surgical interventions to address age-related health issues. Elderly individuals often have weaker immune systems, making them more susceptible to infections after surgery. Also, advances in medical technology and an increasing number of surgical procedures being performed globally have expanded the at-risk population for SSIs.
Opportunities:
Opportunities in the Growing Number of Surgeries
The increasing number of surgeries presents significant opportunities for the Surgical Site Infection Market. As medical advancements continue to progress, the global healthcare landscape is witnessing an increase in the volume of surgical procedures being performed.
With more surgeries taking place, there is a higher demand for infection-prevention products that can help reduce the risk of SSIs. These products include antimicrobial dressings, surgical drapes, gowns, gloves, and other barrier materials designed to create a sterile environment during surgical procedures. As the number of surgical procedures grows, so does the need for effective wound care solutions.
Segmentation Analysis of the Surgical Site Infection Market:
By Product, the Wound Care Dressing segment had the largest market share. Wound care dressings create a barrier over surgical incisions and wounds, protecting them from contamination by bacteria and other microorganisms. By preventing infection at the surgical site, they significantly reduce the risk of SSIs, which is a common complication of surgical procedures.
By Type, Superficial Incisional Infection is likely to dominate in this area. Superficial Incisional Infections are relatively common after surgical procedures, and they can have a considerable impact on a patient’s recovery and well-being. These infections can lead to delayed wound healing, increased pain, prolonged hospital stays, and additional healthcare costs.
Regional Analysis of the Surgical Site Infection Market:
The developed healthcare infrastructure in North America, as well as increasing investments in research activities by many key players in developing innovative treatments of surgical site infection, are expected to keep this region at the forefront of the surgical site infection treatment market over the forecast period. North America's surgical site infections treatment market is expected to grow at a significant rate due to the region's large patient pool, increasing awareness from government organizations, and the increasing prevalence of surgical site infections.
Key Industry Development:
In May 2019, KCI Licensing, Inc. received FDA approval to use PREVENA negative pressure incision system to reduce superficial surgical site infections in patients at high risk of post-op infections.
In October 2018, 3M Company launched SoluPrep Film-Forming Sterile Surgical Solution. The company stated that the new surgical infection control product is a 2% chlorhexidine gluconate and 7055 isopropyl alc surgical skin preparation solution.
